

2025 ANNUAL REPORT

Principal Investigator: Dr. Bishal Gyawali

Co-Investigator: Dr. Laure-Anee Teuwen

Research Assistants: Brian Shkabari and Claire Diana-Gonsalves

Master's Student: Nicole Vorko

Sinclair Cancer Research Institute, Division of Cancer Care and Epidemiology

TABLE OF CONTENTS

LETTER FROM THE PI	2
BG LAB 2025 BY THE NUMBERS	6
PEER-REVIEWED PUBLICATIONS.....	6
MEDIA.....	9
PRESENTATIONS, TALKS, AND MEETINGS.....	9
INTERVIEWS	11
MEDIA RELEASES	11
GRANTS AND AWARDS	12
TRAINEE ACHIEVEMENTS	13
COLLABORATIONS AND PARTNERSHIPS	14

LETTER FROM THE PI

Dear reader,

First of all, thank you very much for being here, reading this. Your support- either as a funder, collaborator, colleague, friend, trainee, mentor, subscriber, patient, member of public, regulator, media person, or any other follower of BG Lab and Cancer Groundshot philosophy- means a lot. It's my pleasure to welcome you to read this first-ever cancer groundshot annual report from the BG Lab.

This report summarizes the activities of BG Lab over 2025 calendar year. We gave somewhat of a formal structure to the BG Lab this summer.

Now we have a dedicated website and X account, and you can subscribe to both to get regular updates from us. While the report gives you an overview of our accomplishments and growth over 2025, let me highlight some notable achievements from 2025, some challenges we need to overcome, and some exciting plans for 2026!

Let's start on a positive note highlighting our accomplishments for 2025. We had a remarkable year, indeed. We had the highest number of publications for any calendar year so far with **27 peer-reviewed publications, highest number of citations for any calendar year with over 1800 citations, and received five international awards in one year!** The awards included [Fellow of ASCO](#), [40 under 40](#) in cancer care, Oncodaily [Yvonne Award](#) - Challenging the Status Quo category, and the recognition of #1 [Highly Ranked Scholar in Global Oncology](#). The [William E. Rawls prize](#) from Canadian Cancer Society is especially meaningful because it is my first national recognition in Canada since I moved to Queen's in 2019.

The core philosophy of BG Lab is Cancer Groundshot, which highlights the need for prioritization in cancer care and research- both nationally and internationally. We are grounded on the principles of patient centered research, global equity in cancer care, and mentorship. These three principles underpin everything we do.

Policy Impact

We have had important policy impact in 2025. Our work has been cited in The 2024 Declaration of Helsinki, as well as policy papers from WHO, ASCO, and ESMO. I was also the only



representative from Canada or Nepal to participate as an expert at the 2025 WHO Essential Medicines List [Expert Committee](#) Meeting, lending my voice to the EML decisions. I also continued to contribute to ASCO policy through the International Affairs Committee and ESMO policy through [MCBS working group](#) and ESMO [public policy committee](#).

Education/Mentorship

In summer, we welcomed [Dr. Laure-Anne Teuwen](#), a medical oncologist from Belgium, as our first international visiting fellow. She spent six weeks at the BG Lab, publishing three papers, doing one presentation, and successfully applying to one grant during that period. She subsequently joined BG Lab as the co-investigator and has been involved with several projects related to global oncology and cancer policy. She has now been selected for the ESMO Leadership Generation Programme.

I am proud of the fact that a trainee has been the first author in 9 of the 16 papers led by BG lab this year. 2 of our trainees have also received awards for their presentation at research meetings this year. We also funded one trainee from Nepal for his travel to ESMO Annual Meeting this year where he made a mini oral presentation.

In addition, I was involved in educational activities all over the world speaking at conferences. But to highlight a couple, teaching at the [ASCO-AIOM research course](#) in Rome was a special pleasure as it was an opportunity to shape the minds of 120 young oncology professionals from Italy, Europe, and beyond. I also chaired an [educational session on pancreas cancer](#) treatment at ASCO 2025, which was very well received with excellent feedback from patient community. And at the end of the year, I was a faculty/mentor at the first Vail-style [5-day research method workshop](#) for Latin America called On-Collab at Sao Paolo, Brazil. We also held the first [BG Lab webinar](#) in December.

We are proud and delighted to announce that BG Lab is accepting both in-person and virtual fellows starting 2026. Please check our new [fellowship page](#) for details.

Global Oncology

In the global oncology front, we published several important papers this year, but special highlight to the paper where we report results from a [qualitative study](#) of Indian oncologists on what factors they consider making treatment decisions, and another paper from Nepal studying the [affordability, availability, and price variations](#) in the price of same cancer drug based on which pharmacy they go to. Also, we did a comprehensive study of [how financial toxicity is being defined in LMICs](#) across the world.

Major Publications

We were able to publish in major journals such as Lancet Oncology, JCO, Annals of Oncology, JNCI, JAMA Oncology, and BMJ Oncology in 2025. Some papers that I'd like to particularly highlight are below. I want to highlight these papers because these papers have huge policy impact.

1. [De-escalation trials](#) can be designed as superiority rather than non-inferiority. Probably my most impactful paper of 2025, because this can change the way we test for de-escalated therapies. I am already receiving emails from major trial groups around the world informing me that some of them have redesigned some of their new trials in accordance with this philosophy.
2. The [Common Sense Oncology principles for designing and reporting RCTs](#) of cancer drugs.
If this checklist is implemented, better patient-centric trials will be designed. If this checklist is employed by journals, publications of RCTs of cancer drugs will not suffer from the biases.
3. [Cost of Convenience in Cancer Care.](#)
This paper offers opportunities for health systems for immediate cost savings without compromising outcomes, as well as, broaches the discussion surrounding how much price we should pay as a society for innovations that only involve convenience. Colleagues in Spain have outlined a nice algorithm for payers based on this paper.
4. [Financial toxicity](#) and its relationship with patient outcomes among participants of clinical trials in Canada.
This paper shows that financial toxicity is present and can continue to worsen among trial participants, and this can be associated with detrimental patient outcomes. This urges a need for policy level action to protect trial participants from financial toxicity.

In addition to these publications, I also joined the Journal of National Cancer Institute (JNCI) as an associate editor in 2025.

Thank You to our Current Funders

We have been fortunate enough to be funded by Ontario Institute for Cancer Research, which provides salary support to me allowing me the time to pursue all these research projects. Early on this year, we also received operating grants from Marathon of Hope Cancer Center Network Patient Voices in Research Initiative, which allowed us to grow from 1 to 5!

Stay Tuned for Future Updates

As we look forward to 2026, BG Lab aims to pursue some larger-scale projects in value-based cancer care and clinical trial methods (also contingent on funding). We are also looking forward to establishing a more structured mentorship programs for trainees both in Canada and across the globe. We are also planning an initiative to share important and inspirational voices in cancer research – an initiative we are planning to pursue through an upcoming BG Lab podcast channel. We will continue our monthly newsletters, and will post more opportunities for collaboration, [fellowships](#), and mentorship, so stay tuned.

How Can You Support Us?

As you read our success stories above, please remember that BG Lab consists of only 5 people at the moment, including myself. We have lots of exciting plans for the future. We have important ideas that we want to work on, that will provide important results for the practice of oncology. We can do so much more! But we are limited by funding. The type of work that we do are not recognized often for funding by traditional funding sources, and get overlooked by basic science research or finding a new target or clinical trials or lately, artificial intelligence. BG Lab doesn't chase the sexiest new thing, but remains committed to conducting high quality research aligned with the philosophy of cancer Groundshot and in accordance with the principles of patient centered research, global equity in cancer care, and mentorship.

If you are a funding agency and believe in the value of the work that we do, [you can support us](#) by:

- Providing unrestricted operating grants
- Providing project specific research grants
- Supporting fellowships

I am incredibly proud of the hard work each member of our team has put into making this year a success. This was a team effort from everyone involved. We thank you all for the continued support.

Thank you,

Bishal Gyawali, MD, PhD, FASCO
Associate Professor, Oncology
Faculty Scientist, Sinclair Cancer Research Institute
Ontario Institute for Cancer Research Clinician-Scientist II
10 Stuart Street, Level 2
Queen's University, Kingston, ON
Canada K7L 3N6

Email: Gyawali.bishal@queensu.ca

Tel: 613-533-6000 ext 78509

www.oncologybg.com

BG LAB 2025 BY THE NUMBERS

4	Awards
1	Grant
27	Publications
24	Presentations
8	Interviews
19	Media releases
9	Trainees supported

PEER-REVIEWED PUBLICATIONS

(Trainees are marked by * and corresponding author status is marked by #)

January	<ol style="list-style-type: none"> 1. Raptis SG*, Shkabari B*, Banday S*, Gyawali B[#]. Defining and measuring financial toxicity in low- and middle-income countries. <i>JCO Oncol Pract</i>. 2025;21(1):57-68. PMID: 39793549 2. Meirson T, Ofer J, Zimhony-Nissim N, Bareket-Samish A, Markel G, Neiman V, Cherny N, Goldstein DA, Gyawali B, Tannock I, Rosenbaum E. Reanalysis of urothelial cancer chemoimmunotherapy trials with differential censoring. <i>JAMA Netw Open</i>. 2025;8(1):e2455630. PMID: 39841472
February	<ol style="list-style-type: none"> 3. Gyawali B, Jung EH, Mooney H, Avorn J, Kesselheim AS. Government Funding for the Development of Enzalutamide. <i>JAMA Oncol</i>. 2025;11(2):182-183. PMID: 39699929 4. Gyawali B, Eisenhauer EA, van der Graaf W, Booth CM, Cherny NI, Goodman AM, Koven R, Pe ML, Marini BL, Mohyuddin GR, Pond GR, Sengar M, Soto-Perez-de-Celis E, Trapani D, Tregear M, Wilson BE, Tannock IF[#]. Common Sense Oncology principles for the design, analysis, and reporting of phase 3 randomised clinical trials. <i>Lancet Oncol</i>. 2025;26(2):e80-e89. PMID: 39914429
March	<ol style="list-style-type: none"> 5. Cherny NI[#], Trapani D, Galotti M, Saar M, Bricalli G, Roitberg F, Gyawali B, Curigliano G, Blay JY, Meier K, Latino NJ, de Vries EGE. ESMO Global Consortium Study on the availability, out-of-pocket costs, and accessibility of cancer medicines: 2023 update. <i>Ann Oncol</i>. 2025;36(3):247-262. PMID: 39818519

April	<p>6. Wright K*, Shkabari B*, Booth C, Knopf K, Tregear M, Gyawali B[#]. Congruence of cancer screening recommendations between the USPSTF and the top ten US cancer centers: a cross sectional study. <i>EClinicalMedicine</i>. 2025;82:103169. PMID: 40235947</p> <p>7. Dee EC, Laversanne M, Bhoo-Pathy N, Ho FDV, Feliciano EJG, Eala MAB, Ting FIL, Ginsburg O, Moraes FY, Gyawali B, Gomez SL, Ng K, Wu JF, Jain U, Jain B, Columbres RC, Matsuda T, Sangrajrang S, Sinuraya ES, Bui TD, Wei W, Won Y, Foo LL, Ling MCA, Mery L, Soerjomataram I, Bray F[#]. Cancer incidence and mortality estimates in 2022 in southeast Asia: a comparative analysis. <i>Lancet Oncol</i>. 2025;26(4):516-528. PMID: 40024257</p> <p>8. Reiss KA, Soares KC, Torphy RJ, Gyawali B[#]. Treatment Innovations in Pancreatic Cancer: Putting Patient Priorities First. <i>Am Soc Clin Oncol Educ Book</i>. 2025;45(3):e473204. PMID: 40173379</p> <p>9. Mittal A*[#], Linford G, Gyawali B. Inferior Control Arms in Prostate Cancer Trials: The ARANOTE Trial. <i>J Clin Oncol</i>. 2025;43(11):1393-1394. PMID: 39823549</p>
May	<p>10. Eisenhauer EA[#], Abdihamid O, Booth CM, Cherny N, Fojo AT, Gyawali B, Marini BL, Mohyuddin GR, Pe M, Pond GR, Soto-Perez-de-Celis E, Tannock EF, Trapani D, Tregear M, van der Graaf WTA, Wilson BE. Guidance for discussants of randomized cancer trials at major meetings. <i>Eur J Cancer</i>. 2025;220:115357. PMID: 40117861</p> <p>11. Leite LF*, Costa de Almeida LF, Diniz da Conceição L, Noronha MM, Belotto M, Saldanha EF, Megid EBC, Peixoto RD, Gyawali B[#]. Disease-free survival as a surrogate for overall survival in early-stage pancreatic cancer trials: a correlation meta-analysis. <i>BMJ Oncol</i>. 2025;4(1):e000766. PMID: 40519225</p> <p>12. Cherny NI[#], Oosting SF, Dafni U, Galotti M, Zygoura P, Dimopoulou G, Amaral T, Barriuso J, Calles A, Kiesewetter B, Gomez-Roca C, Gyawali B, Piccart M, Passaro A, Roitberg F, Tarazona N, Trapani D, Curigliano G, Wester R, Zarkavelis G, Zielinski C, de Vries EGE. ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0). <i>Ann Oncol</i>. 2025;36(8):866-908. PMID: 40409995</p> <p>13. Wilson BE[#], Wright K, Sengar M, Sullivan R, Pearson S, Barton MB, Gyawali B, De Vries E, Moja L, Pramesh CS, Booth CM. Analysis of 2023 World Health Organization cancer Essential Medicines List and concordance with resource-stratified guidelines. <i>J Natl Cancer Inst</i>. 2025;117(10):2010-2020. PMID: 40408185</p>
June	<p>14. Sherry AD, Miller AM, Parlapalli JP, Kupferman GS, Beck EJ, McDonald J, Kouzy R, Jaoude JA, Lin TA, Sanford NN, Chino F, Gyawali B, Booth C, Msaouel P, Ludmir EB. Overall Survival and Quality-of-Life Superiority in Modern Phase 3 Oncology Trials: A Meta-Epidemiological Analysis. <i>JAMA Oncol</i>. 2025;11(7):718-724. PMID: 40451185</p>

July	15. Chen J, Selokar A, Ho FDV, Jacomina LE, Feliciano EJG, Uy JMADL, Wu JF, Jain U, Jain B, Columbres RC, Treechairusame T, Willmann J, Ting FIL, Iyengar P, Moraes FY, Gyawali B , Tangco ED, Flores JA, Chua MLK, Estilo C, Mejia MBA, Lee NY, Dee EC#. Head and Neck Cancer in Southeast Asia: 2022 Incidence, Mortality, and Projections to 2050 . <i>Laryngoscope</i> .
August	16. Teuwen LA*, Gyawali B #. Inferior control arms in oncology trials in LMICs: contextualised or compromised? . <i>BMJ Oncol</i> . 2025;4(1):e000931. PMID: 40909186
September	17. Stevens SX*, Gyawali B #. CodeBreak or code blue? Assessing sotorasib's vital signs in metastatic colorectal cancer . <i>Cancer</i> . 2025;131(17):e70056. PMID: 40831024 18. Teuwen LA*, Pond GR, Gyawali B #. Success in oncology phase 3 trials: a small P value or patient value . <i>J Natl Cancer Inst</i> . 2025;117(9):1761-1763. PMID: 40920131 19. Tannock IF#, Pe ML, Booth CM, Brundage M, Cherny NI, Coens C, Eisenhauer EA, Geissler J, Giesinger JM, Gyawali B , Oosting SF, Pond GR, Reijneveld JC, Soto-Perez-de-Celis E, Tregear M, van der Graaf ETA. Importance of responder criteria for reporting health-related quality-of-life data in clinical trials for advanced cancer: recommendations of Common Sense Oncology and the European Organisation for Research and Treatment of Cancer . <i>Lancet Oncol</i> . 2025;26(9):e499-e507. PMID: 40907528 20. Gyawali B #. Cost of Convenience in Cancer Care . <i>JCO Oncol Pract</i> . 2025. PMID: 40939137
October	21. Hammond A, Ranganathan S, Jain U, Jain B, Iyengar P, Feliciano EJG, Swami N, Wu JF, Gyawali B , Mathew A, Pramesh C, Dee EC#, Bray F, Sengar M. Hematologic cancers in the saarc region: current burden in 2022 and projections to 2050 . <i>Blood Global Hematology</i> . 2025:100036 22. Datta S, Sharma V, Mukherjee A, Agrawal S, Sirohi B, Gyawali B #. Qualitative study of oncologists' perceptions on the US Food and Drug Administration approval status and clinical practice guidelines and their impact on local practice patterns in India . <i>BMJ Oncol</i> . 2025;4(1):e000863. PMID: 41140437
November	23. Gyawali B #, Chen N, Tu D, Pater J. Financial difficulty among patients with cancer participating in clinical trials and its association with patient survival and quality of life . <i>J Natl Cancer Inst</i> . 2025;117(11):2336-2342. PMID: 40811149 24. Shilpakar R#, Shkabari B*, Acharya B, Lamichhane N, Paudel DB, Mukesh Y, Sah SG, Poudyal SB, Gyawali B . Availability, Affordability, and Variations in Price of GI Cancer Medicines in Nepal . <i>JCO Glob Oncol</i> . 2025;(11):e2500328. PMID: 41232056 25. Abdihamid O*, Gyawali B , Booth CM, Eisenhauer EA, Hopman WM, Shkabari B, Trapani D, Verduzco-Aguirre HC, Wilson BE, Tannock IF#.

	<p>Adherence of published randomised Phase 3 cancer trials to principles proposed by common-sense oncology. <i>Eur J Cancer</i>. 2025;230:116041. PMID: 41046634</p> <p>26. Stevens SX*, Teuwen LA*, Gyawali B#. Overall survival assessment in cancer drug trials: a luxury or a necessity?. <i>Lancet Oncol</i>. 2025;26(11):1402-1404. PMID: 41110458</p>
December	<p>27. Gyawali B#. De-escalation trials do not always need to be non-inferiority-A case for superiority design de-escalation trials in oncology. <i>JNCI: Journal of the National Cancer Institute</i>. 2025:djaf322.</p>

MEDIA

PRESENTATIONS, TALKS, AND MEETINGS	
<p>Honouring the Past, Exploring the Future. Keynote Speaker. Queen's University CUCOH, 2025.</p>	January
<p>OncoDaily Global Cancer Movement. The Need for Common Sense Oncology.</p>	January
<p>WHO Essential Medicine List for Cancer Drugs. Expert Panel Member. WHO Headquarters, Geneva.</p>	January
<p>ASCO Guidelines Panel for G-CSF. Chair. ASCO Headquarters, Alexandria, VA.</p>	January
<p>ESMO-EORTC Meeting on Near equivalence trials. EORTC Headquarters, Brussels</p>	February
<p>ASCO-AIOM Clinical Research Methods Course. Invited International Faculty. Rome, Italy.</p>	March
<p>OICR Strategic Planning Meeting, Toronto</p>	April
<p>Common Sense Oncology. Conference Co-Organizer and Co-Host, Speaker. CSO Annual Leadership Meeting, Montreal.</p>	April
<p>25th Expert Committee on Selection and Use of Essential Medicines. Expert Committee Member. WHO Headquarters, Geneva.</p>	May
<p>CSO x SONIA Trial Webinar, Online.</p>	May

Host. Impact of SONIA Trial on Cancer Policy.	
How to critically appraise a phase 3 cancer drug trial? Insights from the CSO RCT Checklist. Named Lecture. The Gosling Lecture (OBGYN Grand Rounds), University of Michigan.	May
CSO Symposium at ASCO 2025. Host and Speaker. Chicago.	June
Treatment Innovations in Pancreatic Cancer: Balancing Hope and Expectations. Session Chair. ASCO 2025 Annual Meeting, Chicago.	June
CSO- ASCO Highlights Webinar. Moderator.	June
Crossover and censoring in cancer drug trials. Grand Rounds Speaker. Combined Oncology Rounds, Northern Ontario School of Medicine, Sudbury	July
ESMO Near-Equivalence Workshop. Project Member. Lugano, Switzerland.	July
ESMO-MCBS Working Group Meeting. Member and Speaker. Lugano, Switzerland.	July
ANZUP Annual Meeting 2025, Sydney, Australia. Keynote Speaker.	July
Mexican Society of Oncology Annual Meeting. Cancun. Keynote Speaker.	September
Advanced Breast Cancer Meeting. Invited Speaker. New Endpoints in Breast Cancer Trials, Lisbon, Portugal.	November
Patient Advocacy Session. Invited Panelist. 11 th Annual Canadian Conference on Epigenetics, Banff, Canada.	November
How do Oncologists in LMICs Make Treatment Decisions? Host and Panelist. BG Lab Webinar, Online.	December

ON-COLLAB International Workshop on Oncology Research Methods, Brazil Invited Faculty and Mentor.	December
INTERVIEWS	
Zoomer Radio. Zommer Week In Review. February 16 2025-60th Anniversary of Canada's Flag & Rethinking Cancer Drug Trials . 2025.	February
CTV News. Joe Biden diagnosed with prostate cancer . 2025.	May
Ecaner. ASCO 2025: Highlights and Analysis .	June
MOHCCN. How Common Sense Oncology Can Help Redefine Precision Medicine and Improve Patient Experiences .	August
CBC News. Ontarians will have quicker access to some new cancer drugs, health minister says . 2025.	October
GU Cast. Let's Talk Common Sense Oncology .	October
OncoDailyTV. Empowering Oncologists: Why is Common Sense foundational in Oncology?	November
CBC News. New research suggests surge in incurable prostate cancer from lack of early screening .	December
Bloomberg. Cancer Doctors are Making a Fortune off Drug-Trial Participants .	December
MEDIA RELEASES	
Medscape. Skills Lab: Assessing the Introduction and Methods Sections .	January
Medscape. Skills Lab: Clinical Trial Methods — Focus on the Control Arm .	January
Medscape. Why Overall Survival Should Be The Oncology Trial Endpoint .	January
Ecaner. A checklist for designing and reporting cancer drug phase 3 clinical trials .	February
Medscape. Skills Lab: The Importance of the Primary Endpoint .	March
Medscape. When a Cancer Drug Shortens Life: Lessons From ARIEL4 .	March
Medscape. Skills Lab: Understanding Surrogate Endpoints and Their Limitations .	March
Medscape. Are Top Cancer Centers Misleading on Screening?	April
Medscape. Skills Lab: Classifying and Defining Surrogate Endpoints .	May
Medscape. Biden's Prostate Cancer Diagnosis: Debunking Misconceptions .	May
Medscape. Skills Lab: Rethinking Surrogate Endpoints Approval .	June
Medscape. Skills Lab: Understanding Misconceptions About PFS in Cancer Care .	June
Medscape. Do Oncology Board Exams Make Us Better Doctors?	July
Medscape. Exercise Intervention Boosts Colon Cancer Survival Benefits .	July

Medscape. Per-Protocol vs ITT: Wrong Analysis Inflates Efficacy.	October
Medscape. What Do P Values Really Mean?	October
Ecancer. ESMO 2025: Highlights and analysis.	October
Medscape. Beyond the Critique: The ESMO Trials That Got It Right.	November
Medscape. ESMO 2025: Look Beyond the Hype and Do the Math.	December
Medscape. Beyond the Hype: Lessons From ESMO 2025 Oncology Trial Data.	December

GRANTS AND AWARDS

TITLE	ORGANIZATION	DATE
GRANTS		
Disparities in access to precision cancer drugs across Canada	Terry Fox Research Institute, Marathon of Hope Cancer Centers Network, Patient Voices in Research Initiative	2025–2026
AWARDS		
40 Under 40 in Cancer	Association for Value-Based Cancer Care <ul style="list-style-type: none"> Awarded out of over 3000 nominations. This award recognizes emerging leaders for their exemplary contributions to the cancer research field. 	May
Yvonne Award for Challenging the Status Quo	OncoDaily <ul style="list-style-type: none"> Awarded out of over 160 nominations globally. This award recognizes innovators and leaders for their achievements in advancing cancer care. 	May
Fellow of the American Society of Clinical Oncology (FASCO)	American Society of Clinical Oncology <ul style="list-style-type: none"> Recognizes exceptional volunteer service, leadership, and dedication to ASCO and to advancing the field of clinical oncology. 	June
2024 William E. Rawls Prize	Canadian Cancer Society <ul style="list-style-type: none"> This award recognizes early-career investigators whose work has provided significant and important advancements in cancer control. 	August

Highly Ranked Scholar – Lifetime, in the Specialty of Oncology	ScholarGPS <ul style="list-style-type: none"> Recognizes exceptional productivity, noteworthy impact and quality of scholarly work in the top 0.05% of scholars in the Specialty worldwide. 	December
--	--	----------

TRAINEE ACHIEVEMENTS

TRAINEE	POSITION	ACHIEVEMENT
Brian Shkabari	Research Assistant	<ul style="list-style-type: none"> Received an award for Outstanding Service for his contributions to Common Sense Oncology. Gave a mini-oral presentation at Queen's Health Sciences Research Day presenting on the FDA cancer drug approval landscape. Gave an oral presentation at Queen's Oncology Research Day discussing our work on the unavailability, unaffordability, and price variations of GI cancer drugs in Nepal. Co-led and published a paper in JCO Global Oncology on the availability, affordability, and price variation of GI cancer medicines in Nepal.
Nicole Vorko	Research Assistant	<ul style="list-style-type: none"> Gave a poster presentation at Queen's Health Sciences Research Day presenting on the Health Canada cancer drug approval landscape – won the best poster award. Gave an oral presentation at Queen's Oncology Research Day discussing results from our study investigating the Health Canada cancer drug approval landscape.
Samuel Stevens	CSO Fellow	<ul style="list-style-type: none"> Published a commentary in Cancer highlighting the need for precision in dosing, endpoints, and trial reporting in the context of the CodeBreak 300 trial. With Laure-Anne Teuwen, published a high-impact paper in The Lancet Oncology highlighting the strengths and weaknesses of the FDA's guidance to overall survival assessment in cancer drug trials.

Laure-Anne Teuwen	Visiting fellow, and now co-investigator at BG Lab	<ul style="list-style-type: none"> • Selected for the ESMO Leadership program 2025-2026. • Presented a poster at the AORTIC 2025 meeting discussing her work from Malawi studying 2-drug versus 3-drug neoadjuvant chemotherapy for locally advanced cervical cancer when radiotherapy is not available. • Published 3 papers in her first month with BG Lab, one in The Lancet Oncology, one in JNCI, and another in BMJ Oncology.
-------------------	--	--

COLLABORATIONS AND PARTNERSHIPS

Dr. Gyawali is the only representative from Canada for the World Health Organization Expert Panel of Selection of Essential Medicines List. He is also a committee member for the International Affairs Committee of American Society of Clinical Oncology (ASCO), and on Public Policy Committee and Magnitude of Clinical Benefit Scale Committee of European Society for Medical Oncology (ESMO). He has been the chair for and on the organizing committee for several international oncology congresses, such as ASCO, ESMO, and World Lung Cancer Conference. Dr. Gyawali also continued collaboration with colleagues from low-and-middle-income countries. Dr. Gyawali attended [ANZUP 2025 Annual Meeting](#) for the first time and gave keynote lectures on the principles of cancer groundshot and common sense oncology in cancer research and media communication. Later, he also gave a keynote at Mexican Oncology Society (SMeO) 2025 to discuss principles of critical appraisal and plans to collaborate on future projects.